Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan Details Revenue Expectations From Newly Acquired Inamed

This article was originally published in The Gray Sheet

Executive Summary

Allergan expects its recently completed acquisition of Inamed to add $355 mil. to $395 mil. in sales revenue this year

You may also be interested in...



Broad Coverage For Lap-Band Helps Grow Allergan’s Obesity Sales

CMS' decision to cover Allergan's Lap-Band laparoscopic adjustable gastric band for Medicare beneficiaries last February helped spark a 33% revenue jump for Allergan's obesity intervention business in 2006

Broad Coverage For Lap-Band Helps Grow Allergan’s Obesity Sales

CMS' decision to cover Allergan's Lap-Band laparoscopic adjustable gastric band for Medicare beneficiaries last February helped spark a 33% revenue jump for Allergan's obesity intervention business in 2006

Allergan builds obesity treatment portfolio

Allergan will pursue FDA approval of EndoArt's EasyBand remote-controlled gastric banding system for treatment of morbid obesity after acquiring the Swiss company for $97 million, the firm announces Feb. 22. The "next-generation" implant, intended for placement around the upper stomach, allows telemetric adjustment via an external controller to fit each patient's individual weight loss needs, the company says. Approved in Europe in mid-2006, EasyBand complements Allergan's Lap-Band adjustable gastric banding system. Allergan gained Lap-Band - currently the only adjustable implant for individualized weight loss approved in the United States - in its $3.2 billion purchase of Inamed last year (1"The Gray Sheet" April 3, 2006, p. 6). Allergan also offers its nonsurgical BIB BioEnterics intragastric balloon for obesity treatment outside the United States...

Related Content

UsernamePublicRestriction

Register

MT023378

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel